Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.
Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...
The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...
Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat ...